Compass Pathways stock reversed higher Tuesday on positive test results for its psychedelic drug in treatment-resistant depression.

Compass Pathways (NASDAQ:CMPS) said new 26-week data from its Phase 3 COMP006 trial further support the durability and safety ...

Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.

COMPASS Pathways stock has delivered a very strong 1 year return, yet its current valuation checks and market multiples point ...

Compass Pathways has announced six‑month results from its second phase 3 trial of COMP360, its synthetic formulation of ...

Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, ...

Compass Pathways Plc shares fell almost 10% Tuesday after a pivotal study of its experimental psilocybin-based therapy ...

Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June LONDON & NEW YORK--(BUSINESS WIRE)--Compass ...

Shares of Compass Pathways climbed after the company said data from a late-stage trial of its drug for treatment-resistant depression confirmed its rapid onset and durable profile. The stock jumped 8.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...

Compass Pathways (CMPS) stock rises as the company posts new late-stage trial data for its psychedelic therapy COMP360 ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...